Repligen (NASDAQ:RGEN) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report released on Tuesday morning,Briefing.com Automated Import reports. The brokerage issued a hold rating and a $165.00 price objective on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on RGEN. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday. They set a “hold” rating and a $165.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $185.20.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $158.14 on Tuesday. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The business’s 50 day moving average price is $143.15 and its 200 day moving average price is $141.68. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.86 billion, a P/E ratio of -427.41, a P/E/G ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the firm earned $0.23 EPS. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Several large investors have recently bought and sold shares of the company. Champlain Investment Partners LLC lifted its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after purchasing an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares in the last quarter. Finally, DF Dent & Co. Inc. raised its position in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.